Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen

Weiser, Mary Ann, Cabanillas, Maria E., Konopleva, Marina, Thomas, Deborah A., Pierce, Sherry A., Escalante, Carmen P., Kantarjian, Hagop M., O'Brien, Susan M.·2004·Cancer

Abstract

BACKGROUND: Hyperglycemia, which is not uncommon during the treatment of acute lymphocytic leukemia (ALL), has been shown to be an independent predictor of adverse outcomes among hospitalized patients with undiagnosed diabetes; it also may have the potential to affect leukemic cell proliferation through altered metabolism. The purpose of the current study was to determine the prevalence of hyperglycemia during induction chemotherapy for ALL using a regimen comprised of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD) and to determine its effect on survival, duration of disease remission, and treatment‐related complications. METHODS: Two hundred seventy‐eight adult patients with previously untreated ALL who achieved a complete remission with the hyper‐CVAD regimen were evaluated. Hyperglycemia was defined as ≥ 2 glucose determinations of ≥ 200 mg/dL during the first 30 days of induction chemotherapy. Induction chemotherapy was comprised of fractionated cyclophosphamide at a dose of 300 mg/m 2 twice daily on Days 1–3, doxorubicin at a dose of 50 mg/m 2 on Day 4, vincristine at a dose of 2 mg on Days 4 and 11, and dexamethasone at a dose of 40 mg on Days 1–4 and Days 11–14 (hyper‐CVAD). Hyper‐CVAD, given in odd‐number courses (Courses 1, 3, 5, and 7), was alternated with methotrexate and cytarabine (MTX/Ara‐C), given in even‐number courses (Courses 2, 4, 6, and 8). MTX/Ara‐C was comprised of MTX at a dose of 200 mg/m 2 over 2 hours followed by 800 mg/m 2 over 22 hours on Day 1, Ara‐C at a dose of 3 g/m 2 every 12 hours for 4 doses over 2 days (Days 2 and 3), and intravenous methylprednisolone given at a dose of 50 mg twice daily on Days 1–3. The complete remission duration (CRD), survival, and treatment‐related complications were determined for patients with and without hyperglycemia; differences between the two groups were assessed using standard statistical methods. RESULTS: Hyperglycemia was found to occur in 103 patients (37%). Patients with hyperglycemia had a shorter median CRD (24 months vs. 52 months; P = 0.001) and a shorter median survival (29 months vs. 88 months; P < 0.001); they also were more likely to develop sepsis (16.5% vs. 8.0%; P = 0.03) or any complicated infection (sepsis, pneumonia, or fungal) (38.8% vs. 25.1%; P = 0.016) compared with patients without hyperglycemia. CONCLUSIONS: Patients with hyperglycemia during induction chemotherapy for ALL with the hyper‐CVAD regimen were found to have a shorter CRD, experience a significant increase in overall mortality, and be at an increased risk for developing complicated infections. Cancer 2004. © 2004 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.20071

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 204

Metadata

Authors
Weiser, M. A., Cabanillas, M. E., Konopleva, M., Thomas, D. A., Pierce, S. A., Escalante, C. P., Kantarjian, H. M., & O'Brien, S. M.
Venue
Cancer
Publisher
Wiley
Published
2004-02-12
Volume
100
Issue
6
Pages
1179-1185
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1971347970
Cited by
204
References
1
FWCI
7.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen. https://app.cochat.ai/papers/10.1002/cncr.20071
The paper
Weiser, M. A., Cabanillas, M. E., Konopleva, M., Thomas, D. A., Pierce, S. A., Escalante, C. P., Kantarjian, H. M., & O'Brien, S. M. (2004). Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen. Cancer. https://doi.org/10.1002/cncr.20071

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.